£14.0M
The Series C round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund to support international expansion and clinical studies.
"We would like to thank all the investors that participated, including Parkwalk and Boehringer Ingelheim Venture Fund for their continued support, and welcome Hostplus, all of whom recognise the transformative impact that our technology can have on treatment for stroke and lung fibrosis patients. We will continue to harness our position and experience as a European market leader to achieve broad success in the US, helping improve patient care and access to life-changing therapies."
Parkwalk Advisors + 3 others
